JP2025026846A5 - - Google Patents
Info
- Publication number
- JP2025026846A5 JP2025026846A5 JP2024187067A JP2024187067A JP2025026846A5 JP 2025026846 A5 JP2025026846 A5 JP 2025026846A5 JP 2024187067 A JP2024187067 A JP 2024187067A JP 2024187067 A JP2024187067 A JP 2024187067A JP 2025026846 A5 JP2025026846 A5 JP 2025026846A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- pharmaceutical composition
- inhibitor
- mcc
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752382P | 2018-10-30 | 2018-10-30 | |
| US62/752,382 | 2018-10-30 | ||
| PCT/US2019/058319 WO2020092221A1 (en) | 2018-10-30 | 2019-10-28 | Method of treatment of p53 wt tumors |
| JP2021522967A JP7653907B2 (ja) | 2018-10-30 | 2019-10-28 | ｐ５３ＷＴ腫瘍の処置の方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522967A Division JP7653907B2 (ja) | 2018-10-30 | 2019-10-28 | ｐ５３ＷＴ腫瘍の処置の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025026846A JP2025026846A (ja) | 2025-02-26 |
| JP2025026846A5 true JP2025026846A5 (https=) | 2025-10-10 |
Family
ID=68582462
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522967A Active JP7653907B2 (ja) | 2018-10-30 | 2019-10-28 | ｐ５３ＷＴ腫瘍の処置の方法 |
| JP2024187067A Pending JP2025026846A (ja) | 2018-10-30 | 2024-10-24 | ｐ５３ＷＴ腫瘍の処置の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522967A Active JP7653907B2 (ja) | 2018-10-30 | 2019-10-28 | ｐ５３ＷＴ腫瘍の処置の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12115151B2 (https=) |
| EP (1) | EP3873460B1 (https=) |
| JP (2) | JP7653907B2 (https=) |
| KR (1) | KR102879859B1 (https=) |
| CN (1) | CN112996503A (https=) |
| AU (1) | AU2019369216B2 (https=) |
| CA (1) | CA3115716A1 (https=) |
| ES (1) | ES2986421T3 (https=) |
| IL (1) | IL282485B2 (https=) |
| WO (1) | WO2020092221A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| CN115216514B (zh) * | 2022-08-01 | 2026-03-17 | 中国科学技术大学 | Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388093B (es) * | 2016-11-15 | 2025-03-19 | Novartis Ag | Dosis y regimen para inhibidores de la interaccion hdm2-p53. |
-
2019
- 2019-10-28 WO PCT/US2019/058319 patent/WO2020092221A1/en not_active Ceased
- 2019-10-28 KR KR1020217015953A patent/KR102879859B1/ko active Active
- 2019-10-28 JP JP2021522967A patent/JP7653907B2/ja active Active
- 2019-10-28 IL IL282485A patent/IL282485B2/en unknown
- 2019-10-28 AU AU2019369216A patent/AU2019369216B2/en active Active
- 2019-10-28 US US17/289,122 patent/US12115151B2/en active Active
- 2019-10-28 ES ES19805046T patent/ES2986421T3/es active Active
- 2019-10-28 CA CA3115716A patent/CA3115716A1/en active Pending
- 2019-10-28 CN CN201980070367.1A patent/CN112996503A/zh active Pending
- 2019-10-28 EP EP19805046.0A patent/EP3873460B1/en active Active
-
2024
- 2024-10-24 JP JP2024187067A patent/JP2025026846A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025026846A5 (https=) | ||
| Yun et al. | Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front–mutant ROS1-rearranged non–small cell lung cancer | |
| Daver et al. | FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm | |
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| Saygin et al. | Emerging therapies for acute myeloid leukemia | |
| Bouwman et al. | Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? | |
| Akashi et al. | Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status | |
| JP2019502669A5 (https=) | ||
| Patyna et al. | SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity | |
| Johnson et al. | Update on the targeted therapy of melanoma | |
| Bailón-Moscoso et al. | Development of anticancer drugs based on the hallmarks of tumor cells | |
| JP2019142930A5 (https=) | ||
| JP2019513694A5 (https=) | ||
| JP2019507721A5 (https=) | ||
| JP2018526376A5 (https=) | ||
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| Kircher et al. | Targeting angiogenesis in colorectal cancer: tyrosine kinase inhibitors | |
| Braiteh et al. | Uncommon tumors and exceptional therapies: paradox or paradigm? | |
| Penel et al. | O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma | |
| Altan et al. | Management of small cell lung cancer: progress and updates | |
| Desai et al. | Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options | |
| Moore et al. | The role of biomarkers in guiding clinical decision-making in oncology | |
| Dabney et al. | Molecular pathways and targeted therapy in cholangiocarcinoma | |
| JP2018516936A5 (https=) | ||
| Hong et al. | Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer |